Purdue Pharmaceutical Products LP will commit $19 million to a six-month direct-to-consumer (DTC) advertising program for Intermezzo (zolpidem tartrate), the insomnia drug developed by Transcept Pharmaceuticals Inc., which is kicking in an additional $10 million toward the effort.